Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
5x-Multiplier vs 3-Tier Model for Discharge Opioid Prescriptions After Intra-abdominal Cancer Surgery
NCT06232577Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2024
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of hydrocodone, tramadol and oxycodone in postoperative pain (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Safety and adverse events at 1 year, Initial oral morphine equivalent prescribed upon discharge and 1 more. Started Mar 2024; status: completed.
02
Drugs
hydrocodonetramadoloxycodone
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT06232577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06232577.